<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03375463</url>
  </required_header>
  <id_info>
    <org_study_id>16671</org_study_id>
    <secondary_id>I8F-MC-GPGE</secondary_id>
    <nct_id>NCT03375463</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide (LY3298176) in Healthy Participants</brief_title>
  <official_title>Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has three parts. Each participant will enroll in one part.

      Part A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a
      powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part
      A will measure how much of the study drug gets into the blood stream and how long it takes
      the body to get rid of it.

      Part B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide
      intravenous (IV) formulation when administered into a vein.

      Part C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide
      following multiple SC weekly doses of a solution.

      This study will last approximately 70 days for Part A or Part B and 92 days for Part C. This
      does not include screening. Screening is required within 28 days prior to the start of the
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2017</start_date>
  <completion_date type="Actual">December 27, 2018</completion_date>
  <primary_completion_date type="Actual">December 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part A and Part B are not blinded. Part C is blinded to Participant and Investigator</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) Part A: Area Under the Concentration versus Time Curve (AUC) of Tirzepatide</measure>
    <time_frame>Baseline up to 37 days</time_frame>
    <description>PK: AUC of tirzepatide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) Part A: Maximum Observed Drug Concentration (Cmax) of Tirzepatide</measure>
    <time_frame>Baseline up to 37 days</time_frame>
    <description>PK: Cmax of tirzepatide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) Part B: Area Under the Concentration versus Time Curve (AUC) of Tirzepatide</measure>
    <time_frame>Baseline at least 70 days</time_frame>
    <description>PK: AUC of tirzepatide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Part C: Area Under the Concentration versus Time Curve (AUC) of Tirzepatide</measure>
    <time_frame>Baseline at least 92 days</time_frame>
    <description>PK: AUC of tirzepatide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Part C: Maximum Observed Drug Concentration (Cmax) of Tirzepatide</measure>
    <time_frame>Baseline at least 92 days</time_frame>
    <description>PK: Cmax of tirzepatide</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tirzepatide Test Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC dose of tirzepatide solution formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Reference Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC dose of tirzepatide lyophilized formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Formulation Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV dose of tirzepatide formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tirzepatide Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titrated SC doses of tirzepatide solution formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC dose of placebo matching tirzepatide dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide Part C</arm_group_label>
    <arm_group_label>Tirzepatide Reference Part A</arm_group_label>
    <arm_group_label>Tirzepatide Test Part A</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Tirzepatide Formulation Part B</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males or females, as determined by medical history and physical
             examination

          -  Male participants: agree to use an effective method of contraception for the duration
             of the study and for 3 months following the last dose of investigational product

          -  Female participants: not of childbearing potential due to surgical sterilization
             (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Women with an
             intact uterus are deemed postmenopausal if they are greater than or equal to (≥)45
             years old and have not taken hormones or oral contraceptives within the last year and
             had cessation of menses for at least 1 year. Or, have had at least 6 months of
             amenorrhea with follicle-stimulating hormone levels consistent with a postmenopausal
             state

          -  Have a body mass index of 18.5 to 32.0 kilograms per meter squared (kg/m²) inclusive

        Exclusion Criteria:

          -  Currently enrolled in a clinical trial involving an investigational product or any
             other type of medical research judged not to be scientifically or medically compatible
             with this study

          -  Received treatment with a drug that has not received regulatory approval for any
             indication within 30 days of screening

          -  Have a history of heart block, or a pulse rate (PR) interval greater than (&gt;)200
             milliseconds (msec), or any abnormality in the 12-lead electrocardiogram (ECG) at
             screening that, in the opinion of the investigator, increases the risks associated
             with participating in the study

          -  Have a significant history of or current cardiovascular (myocardial infarction,
             congestive heart failure, cerebrovascular accident, venous thromboembolism, etc.),
             respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological
             (including history of thrombocytopenia), or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs, or of
             constituting a risk when taking the study medication, or interfering with the
             interpretation of data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 13, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2017</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

